We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Drugmakers Seek More Details on LPAD Pathway Draft Guidance
Drugmakers Seek More Details on LPAD Pathway Draft Guidance
Merck and GlaxoSmithKline called for more information from the FDA in comments on the agency’s draft guidance for sponsors using the limited population pathway for antibacterial and antifungal drugs (LPAD).
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor